News

Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis
Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...
Knowridge Science Report11d
Single-dose RSV vaccine protects older adults across three seasons, global study finds
A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...
News-Medical.Net on MSN8d
One RSV shot cuts severe lung infections in older adults for three seasons, trial shows
A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...
Pharmabiz13d
ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease
the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...
24/7 Wall St. on MSN7d
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...
Study finds lab-created antibody effective in preventing severe respiratory illness in infants
The researchers said that efficacy of nirsevimab seen in the controlled settings of a clinical trial may not fully reflect ...
Medscape13d
ACIP Backs RSV Shot for Some 50- to 59-Year-Olds, New Meningitis Vaccine
At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...